8-K - Soligenix, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Soligenix, Inc. issued a shareholder update letter detailing clinical progress across its pipeline, including the ongoing Phase 3 FLASH 2 trial for HyBryte™ and positive Phase 2a results for SGX945 and SGX302. The company reported having sufficient capital to meet goals through 2026 and continues to evaluate strategic options.

Key Takeaways

1The confirmatory Phase 3 FLASH 2 clinical trial for HyBryte™ has enrolled 66 patients as of February 10, 2026, with interim analysis expected in 2Q 2026.

2Top-line results for the Phase 3 FLASH 2 trial are expected in the second half of 2026.

3In an investigator-initiated study, 75% of evaluable patients achieved 'Treatment Success' following 18 weeks of HyBryte™ treatment.

4The company reported approximately $10.5 million in cash as of September 30, 2025, providing sufficient capital through 2026.

5The company expects peak annual net sales of HyBryte™ in the U.S. to exceed $90 million.

6Soligenix continues to evaluate strategic options, including partnership and merger and acquisition opportunities.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On February 12, 2026, Soligenix, Inc. (the “Company”) issued a press release providing a shareholder update letter from its President and Chief Ex

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated February 12, 2026 104 Cover Page Interacti

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1